Abstract:Key PointsIn contrast to all other known prolyl isomerases, PIN1 has the unique property of binding to and catalysing the conversion of specific proline-directed serine/threonine phosphorylation motifs between the two distinct cis and trans conformations of proline. Such PIN1-catalysed prolyl isomerization functions as a molecular timer that modulates many targets at various steps of a given cellular process to synchronously control the amplitude and duration of a given cellular response or process.PIN1 is tightly regulated under physiological conditions, but is commonly overexpressed and/or overactivated in most human cancers, with its levels being correlated with clinical outcome in many cancers. By contrast, PIN1 polymorphisms that lower PIN1 expression are associated with reduced risk for multiple cancers.Pin1-null mice, which develop normally, are highly resistant to tumorigenesis even after overexpression of oncogenes or ablation of tumour suppressors. Conversely, PIN1 overexpression disrupts cell cycle coordination and leads to chromosome instability and tumorigenesis.Abnormal PIN1 activation disrupts the balance in cancer to activate at least 40 oncogenes and inactivate at least 20 tumour suppressors, many of which have a known role in cancer stem cells (CSCs).PIN1 inhibitors have the promising and desirable property of restoring the balance in cancer by simultaneously blocking many cancer-driving pathways in cancer cells and CSCs for treating aggressive and drug-resistant cancers. PIN1 is a major target of the drug all-trans retinoic acid (ATRA) in acute promyelocytic leukaemia.The recent development of cis and trans conformation-specific antibodies provides direct evidence for conformation-specific function and regulation by PIN1, and should facilitate the discovery of novel disease mechanisms and potential new therapies for PIN1-related diseases. Further development of conformation-specific antibodies against oncogenes and tumour suppressors that are PIN1 substrates would provide powerful tools for studying cancer signalling and may lead to new cancer diagnostics and/or therapeutics.

Computational and Structure-Based Development of High Potent Cell-Active Covalent Inhibitor Targeting the Peptidyl-Prolyl Isomerase NIMA-Interacting-1 (Pin1)

Identification of a potent and selective covalent Pin1 inhibitor

Small molecules targeting Pin1 as potent anticancer drugs

Recent advances of Pin1 inhibitors as potential anticancer agents

Re-Evaluating PIN1 as a Therapeutic Target in Oncology Using Neutral Inhibitors and PROTACs

Membrane permeable cyclic peptidyl inhibitors against human Peptidylprolyl Isomerase Pin1.

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth<i>in vivo</i>

Sulfopin, a selective covalent inhibitor of Pin1, blocks Myc-driven tumor initiation and growth in vivo

Targeting Pin1 for Modulation of Cell Motility and Cancer Therapy

A covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action

Discovery of potent PROTAC degraders of Pin1 for the treatment of acute myeloid leukemia

Sulfopin is a covalent inhibitor of Pin1 that blocks Myc-driven tumors in vivo

Pin1: Advances in pancreatic cancer therapeutic potential and inhibitors research

Integrating computational methods guided the discovery of phytochemicals as potential Pin1 inhibitors for cancer: pharmacophore modeling, molecular docking, MM-GBSA calculations and molecular dynamics studies

Prolyl isomerase Pin1: a promoter of cancer and a target for therapy

Discovery of (R)-5-((5-(1-methyl-1h-pyrazol-4-yl)-4-(methylamino)pyrimidin-2-yl)amino)-3-(piperidin-3-yloxy)picolinonitrile, a Novel CHK1 Inhibitor for Hematologic Malignancies.

The isomerase PIN1 controls numerous cancer-driving pathways and is a unique drug target

The role of the master cancer regulator Pin1 in the development and treatment of cancer

Pancreatic tumor eradication via selective Pin1 inhibition in cancer-associated fibroblasts and T lymphocytes engagement

Pin1 WW Domain Ligand Library Synthesized with an Easy Solid-Phase Phosphorylating Reagent

Synthesis and structure-activity optimization of azepane-containing derivatives as PTPN2/PTPN1 inhibitors